Literature DB >> 10336671

Neuroprotective actions of peripherally administered insulin-like growth factor I in the injured olivo-cerebellar pathway.

A M Fernandez1, A G Gonzalez de la Vega, B Planas, I Torres-Aleman.   

Abstract

Exogenous administration of insulin-like growth factor I (IGF-I) restores motor function in rats with neurotoxin-induced cerebellar deafferentation. We first determined that endogenous IGFs are directly involved in the recovery process because infusion of an IGF-I receptor antagonist into the lateral ventricle blocks gradual recovery of limb coordination that spontaneously occurs after partial deafferentation of the olivo-cerebellar circuitry. We then analysed mechanisms whereby exogenous IGF-I restores motor function in rats with complete damage of the olivo-cerebellar pathway. Treatment with IGF-I normalized several markers of cell function in the cerebellum, including calbindin, glutamate receptor 1 (GluR1), gamma-aminobutyric acid (GABA) and glutamate, which are all depressed after 3-acetylpyridine (3AP)-induced deafferentation. IGF-I also promoted functional reinnervation of the cerebellar cortex by inferior olive (IO) axons. In the IO, increased expression of bax in neurons and bcl-X in astrocytes after 3AP was significantly reduced by IGF-I treatment. On the contrary, IGF-I prevented the decrease in poly-sialic-acid neural cell adhesion molecule (PSA-NCAM) and GAP-43 expression induced by 3AP in IO cells. IGF-I also significantly increased the number of neurons expressing bcl-2 in brainstem areas surrounding the IO. Altogether, these results indicate that subcutaneous IGF-I therapy promotes functional recovery of the olivo-cerebellar pathway by acting at two sites within this circuitry: (i) by modulating death- and plasticity-related proteins in IO neurons; and (ii) by impinging on homeostatic mechanisms leading to normalization of cell function in the cerebellum. These results provide insight into the neuroprotective actions of IGF-I and may be of practical consequence in the design of new therapeutic approaches for neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10336671     DOI: 10.1046/j.1460-9568.1999.00623.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  19 in total

1.  Long-term in vivo time-lapse imaging of synapse development and plasticity in the cerebellum.

Authors:  Naoko Nishiyama; Jeremy Colonna; Elise Shen; Jennifer Carrillo; Hiroshi Nishiyama
Journal:  J Neurophysiol       Date:  2013-10-16       Impact factor: 2.714

Review 2.  The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease.

Authors:  Bhumsoo Kim; Sarah E Elzinga; Rosemary E Henn; Lisa M McGinley; Eva L Feldman
Journal:  Neurobiol Dis       Date:  2019-07-23       Impact factor: 5.996

3.  Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy.

Authors:  E Carro; J L Trejo; S Busiguina; I Torres-Aleman
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

Review 4.  Serum growth factors and neuroprotective surveillance: focus on IGF-1.

Authors:  I Torres-Aleman
Journal:  Mol Neurobiol       Date:  2000-06       Impact factor: 5.590

Review 5.  Spinocerebellar degenerations: an update.

Authors:  Susan L Perlman
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 6.  Growth factors as mediators of exercise actions on the brain.

Authors:  M Llorens-Martín; I Torres-Alemán; José L Trejo
Journal:  Neuromolecular Med       Date:  2008-02-20       Impact factor: 3.843

7.  Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulin-like growth factor I signaling.

Authors:  David Dávila; Ignacio Torres-Aleman
Journal:  Mol Biol Cell       Date:  2008-02-20       Impact factor: 4.138

8.  Past, present and future therapeutics for cerebellar ataxias.

Authors:  D Marmolino; M Manto
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

9.  Endogenous estrogen formation is neuroprotective in model of cerebellar ataxia.

Authors:  Amanda Sierra; Iñigo Azcoitia; Luis Garcia-Segura
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

Review 10.  Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration.

Authors:  Gwenn A Garden; Albert R La Spada
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.